<DOC>
	<DOC>NCT01074632</DOC>
	<brief_summary>The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.</brief_summary>
	<brief_title>Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Male and female 18 to 65 years of age BMI &gt;= 19.5 and &lt;= 37 kg/m2 No clinically relevant abnormal laboratory values History or presence of renal or hepatic insufficiency Participated in a clinical trial in the past 30 days Use of con meds that prolong the QT/QTc taken within 14 days prior to study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>